E156 Micro-Paper · Africa Clinical Trials

The Zero-Trial Nations

Several African nations have fewer than 5 lifetime clinical trial registrations ...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
The Zero-Trial Nations by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
No data
Regional Comparison Africa US Europe 0 50000 100000 150000 200000
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
No data
Research Profile Volume Growth Phase3 Complete Diversity
Enrollment Distribution Africa Reference 10000 20000 30000
The Zero-Trial Nations Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Why It Matters

Several African nations have fewer than 5 lifetime clinical trial registrations — effectively zero participation in global evidence generation despite populations in the millions. These nations are invisible to evidence-based medicine.

In the spatial mapping of African clinical research, does the pattern of the zero-trial nations reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Bayesian posterior trial rate as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. Shannon entropy of the trial distribution was 2.46 bits, confirming substantial concentration beyond random variation. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Question

In the spatial mapping of African clinical research, does the pattern of the zero-trial nations reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Bayesian posterior trial rate as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.

Interpretation

Shannon entropy of the trial distribution was 2.

Boundary

46 bits, confirming substantial concentration beyond random variation.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.